PROTALIX BIOTHERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.145 USD | +1.33% |
|
+1.79% | -35.96% |
| May. 10 | Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
| May. 10 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Evolution of the average Target Price on Protalix BioTherapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
e3660b4d4b4d1b.rRLNm6A8MLczP2Exu5RNqyAoNlfui7GFl7gh2y3_LAw.miKEzOFXW-gHDgMFz_8q03NRVWWg4PC3-otEvWG5SXSVUKr0y2l98QJOEg~d85675e25f09936fd43e9cc1b60c6e94
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.13
USD
Average target price
12
USD
Spread / Average Target
+961.95%
High Price Target
14
USD
Spread / Highest target
+1,138.94%
Low Price Target
10
USD
Spread / Lowest Target
+784.96%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Protalix BioTherapeutics, Inc.
| HC Wainwright |
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- PLX Stock
- Consensus Protalix BioTherapeutics, Inc.
